• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, May 10, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS

Chronic pain alters how DNA works in brain

Bioengineer by Bioengineer
February 16, 2013
in NEWS
Reading Time: 2 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The team led by Prof. Laura Stone, a professor at the Faculty of Dentistry and the Alan Edwards Centre for Research on Pain, and Prof. Moshe Szyf, a professor at the Faculty of Medicine’s Department of Pharmacology and Therapeutics, have discovered a mechanism that embeds the memory of an injury in the way the DNA is marked in the brain by a chemical coating called methyl groups or DNA methylation. The researchers report in the journal PLOS One, that if the symptoms of chronic pain are attenuated, the abnormal changes in DNA methylation could be reversed.

Research pioneered at McGill has previously shown that experiences and not solely chemicals alter the way genes are marked epigenetically, impacting our behavior and well-being. DNA methylation, an epigenetic mark on the gene itself, can therefore serve as a “memory” of an experience that will alter the way the gene functions long after the original experience is gone.  The crucial difference between “genetic” and “epigenetic” causes for disease is that genetic changes are inherited and fixed, while epigenetic changes in contrast are possibly reversible.

The McGill research is the first to link chronic pain to genome-wide epigenetic changes in the brain. “Injury results in long-term changes to the DNA markings in the brain; our work shows  it might be possible to reverse the effects of chronic pain by interventions using either behavioral or pharmacological means that interfere with DNA methylation, says Prof. Szyf. ”Our findings have the potential to completely alter the way we treat chronic pain.”

In this study, the researchers show that behavioral interventions that reverse chronic pain also remove differences in DNA methylation in the brain.

The team report alterations in global DNA methylation are observed in the prefrontal cortex (PFC) and amygdala of mice many months following injury to a nerve, and that environmental enrichment reduces both the pain and the pathological changes in PFC global methylation. They also found that the total amount of global methylation in the PFC significantly correlates with pain severity. 

“These results suggest that epigenetic modulation mediates chronic pain-related alterations in the central nervous system (CNS), forming a “memory trace” for pain in the brain that can be targeted therapeutically, says Stone. Since epigenetics respond to environmental changes, these mechanisms represent a mind-body link between chronic pain and the brain at the genomic level. “The implications of this work are wide reaching and may alter the way we think about chronic pain diagnosis, research and treatment”.

Story Source:

The above story is reprinted from materials provided by McGill University.

Image by nicolesy on flick (Thanks)

Tags: Bioengineeringepigenetics
Share12Tweet8Share2ShareShareShare2

Related Posts

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

May 10, 2026

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

May 10, 2026

Urdu Fall Risk Questionnaire Adapted for Elderly

May 10, 2026

Key Pharmacological Markers for HIV Prevention in MSM

May 10, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    840 shares
    Share 336 Tweet 210
  • New Study Reveals Plants Can Detect the Sound of Rain

    727 shares
    Share 290 Tweet 181
  • Scientists Investigate Possible Connection Between COVID-19 and Increased Lung Cancer Risk

    68 shares
    Share 27 Tweet 17
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

Urdu Fall Risk Questionnaire Adapted for Elderly

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.